We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis to Launch Phase 3 Hydroxychloroquine Trial for COVID-19
Novartis to Launch Phase 3 Hydroxychloroquine Trial for COVID-19
Novartis said it will begin enrollment in the next few weeks for a phase 3 clinical trial to evaluate hydroxychloroquine for treatment of hospitalized COVID-19 patients. The trial will include more than 440 participants at more than a dozen U.S. sites.